Material Event Form 8 K

CytoSorbents Corporation (the "Company") has authorized the offer and sale of the Company's common stock, $0.001 par value per share (the "Common Stock"), in an "at the market" equity offering under a Registration Statement on Form S-3 (No. 333-281062) filed with the Commission on July 26, 2024, as amended by an amendment filed on September 26, 2024, which was declared effective by the U.S. Securities Exchange Commission on September 30, 2024, pursuant to the terms of the Open Market Sale Agreement^SM, dated December 30, 2021, by and between the Company and Jefferies LLC, with a maximum aggregate offering amount of up to $20,000,000 of Common Stock (the "Offered Shares").

Morgan, Lewis & Bockius LLP, counsel to the Company, has issued a legal opinion relating to the legality of the issuance and the sale of the Offered Shares. A copy of such legal opinion is attached as Exhibit 5.1 hereto.